JubliApp™ APK 無料ダウンロード ために アンドロイド ©  Bausch Health Companies Inc
ダウンロード JubliApp™ をインストールする 最新 APK ダウンローダ

JubliApp™ APK 1.1

3.1/5

最後のバージョン: 1.1
DMCAポリシー

最新バージョンを入手する: JubliApp™ アプリ から Medical ために Android. JubliApp - Helping you stay on track with your treatment JubliApp is a tool to help you stay on track with daily treatment of JUBLIA ® (efinaconazole) Topical Solution, 10%. Once you have... 続きを読む >

4 votes, 3.1 stars

JubliApp™   com.valeant.JubliApp   アプリの詳細

ダウンロード機能を壊す
AdBlock&Tracking Protectionを無効にする!


PokEvolver - Pokemon Go Trainers Toolkit- evolution calculator, pokemon location MAP coordinates, gym battle simulator, IV calculator

JubliApp™   スクリーンショット

JubliApp™
JubliApp™

JubliApp™   説明

編集者のレビュー

JubliApp™ is a Medical アプリ for Android phones and tablets developed by Bausch Health Companies Inc. The latest APK version of JubliApp™ is 1.1 compatible with Nexus, Sumsung Galaxy, LG, Huawei and Kindle Fire mobile phones and android devices having system version 4.2 and higher. The last mod was released on 17-7-2018 and has google play package name com.valeant.JubliApp. Please read the details about the アプリ below. Easy and fast JubliApp™ APK download of the android version 1.1 is available directly on ApkGain.com. JubliApp™ APK is the property and trademark from the developer Bausch Health Companies Inc. Please note that we only provide the original and free apk package installation without any modifications. Check our "safe download" sign to get the latest report from McAfee to see if the JubliApp™ download is completely secure. Customers who installed and used this アプリ gave over 4 user ratings with an average rating 3.0 of 5 stars relating to JubliApp™. More than 4 people have used this アプリ by now. Join them now and download JubliApp™ アプリ APK directly on our ApkGain.com play market!


説明

JubliApp - Helping you stay on track with your treatment

JubliApp is a tool to help you stay on track with daily treatment of JUBLIA ® (efinaconazole) Topical Solution, 10%. Once you have set up your personal profile, you’ll have the opportunity to track daily applications, capture weekly progress photos, and participate in a game while waiting for treatment to dry.

By downloading the JubliApp, you can:
• Track daily treatment
• Take progress photos
• Play a game
• Get rewards

With a weekly progress report of your personal results, you’ll soon be on your way to completing treatment!

Please see Important Safety Information below and full Prescribing Information for JUBLIA, including Patient Information and Instructions for Use at www.valeant.com/Portals/25/Pdf/PI/Jublia-PI.pdf.

INDICATION
JUBLIA (efinaconazole) Topical Solution, 10% is a prescription medicine used to treat fungal infections of the toenails.

IMPORTANT SAFETY INFORMATION
•JUBLIA is for use on nails and surrounding skin only. Do not use JUBLIA in your mouth, eyes, or vagina. Use it exactly as instructed by your doctor.
•It is not known whether JUBLIA is effective in children.
•Before you use JUBLIA, tell your doctor about all your medical conditions, including if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed, because it is not known whether JUBLIA can harm an unborn fetus or nursing infant.
•Tell your doctor about all medications you are taking, and whether you have any other nail infections.
•JUBLIA is flammable. Avoid heat and flame while applying JUBLIA to your toenail.
•JUBLIA may cause irritation at the treated site. The most common side effects include: ingrown toenail, redness, itching, swelling, burning or stinging, blisters, and pain. Tell your doctor about any side effects that bother you or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

®/TM are trademarks of Ortho Dermatologics' affiliated entities. © 2018 All Rights Reserved JUB.0076.USA.18
ダウンロードとインストール 無料 アンドロイド apk ファイル ために JubliApp™.

      バージョン履歴

    JubliApp™ 1.1

    2018-07-17
    新着情報: Bug fixes and performance improvements
    レビュー:

    新着情報

    COMMENTS